

Respiratory syncytial virus (RSV) vaccine

Respiratory syncytial (RSV) is a common virus that often causes mild cold-like symptoms. However, in some cases, it can lead to more serious infections, such as bronchiolitis (inflammation of the small airways in the lungs) or pneumonia (lung infection). Certain groups, including infants and older adults, are at higher risk of developing severe RSV and may require hospitalization. Learn more about the respiratory syncytial virus at www.healthlinkbc.ca/healthwise/respiratory-syncytial-virus-rsv-infection

Where to get the RSV vaccine

Use the [Clinic Locator](#) on the BC Pharmacy Association website to find a pharmacy with the RSV vaccine. Please book online or call to make an appointment. The RSV vaccine is not free in B.C. Some private health insurance plans may cover the cost of the vaccine, so be sure to check with your insurance provider for details.

Vaccines for older adults

Health Canada has approved 2 new vaccines to protect older adults from RSV although not currently available through the publicly funded immunization program in British Columbia.

- RSVPreF3 (AREXVY™)
- RSVpreF (ABRYSVO™)

Both are approved for adults 60 years of age and older.

Canada's National Advisory Committee on Immunization recommends the RSV vaccine for:

- Adults 75 and older, especially those who are at increased risk of severe RSV disease
- Adults 60 years and older who are residents of nursing homes and other chronic care facilities

Adults 60 to 74 years of age who would like the vaccine should talk to their health care provider

about whether getting the vaccine is right for them.

RSV vaccination should be considered at an earlier age for adults who live in or are part of some First Nations, Métis, and Inuit communities as they have an increased risk of illness due to structural inequity.

The vaccine works best when given just before or during the RSV season. In B.C., RSV infections often occur in the late fall to early spring. The vaccine is given as one dose.

Protecting infants & young children from RSV

Currently, there is no RSV vaccine approved for infants and young children. However, there are two types of products that can help protect them from RSV infection:

- Monoclonal antibody medications (palivizumab and nirsevimab)
- RSV vaccine for pregnant people (called ABRYSVO™)

Both provide protection through passive immunity.

What is passive immunity?

Passive immunity happens when a person receives antibodies (proteins that fight off germs) from another source instead of producing them on their own through infection or vaccination. This provides immediate protection against infections, but it's temporary because the body isn't producing its own antibodies.

Monoclonal antibody medications

Monoclonal antibody medications (palivizumab and nirsevimab) can be given to infants and young children to help prevent severe illness from

RSV. Unlike vaccines, which help the body make its own antibodies, monoclonal antibodies provide protection by directly transferring antibodies to the baby through an injection.

How it works: These antibodies specifically target RSV to help prevent severe infection.

Protection: These medications provide immediate but temporary protection. Nirsevimab can protect infants for up to 5 months after it is provided.

Availability in BC: Monoclonal antibodies will not be available for most infants in B.C. during the 2025-2026 RSV season. Currently, these medications are available only to certain infants and young children through the BC Infant Respiratory Syncytial Virus (RSV) Immunoprophylaxis Program, who meet specific criteria, such as:

- Young, premature babies with chronic medical conditions
- Infants and young children with major heart or lung conditions
- Infants living in some remote communities where healthcare access is more limited

Cost: These medications are free for children who are eligible through the BC RSV Immunoprophylaxis Program. They are not available for private purchase.

RSV vaccine for pregnant people

Monoclonal antibodies will not be available for most infants during the 2025-2026 RSV season. However, the pregnancy RSV vaccine, ABRYSVO™, remains a good way to protect most healthy infants against RSV infections.

ABRYSVO™ is approved for pregnant people aged 18 and older and is the same vaccine that is approved for adults aged 60 and older. The

purpose of the vaccine during pregnancy is to protect the baby after birth. When a pregnant person receives the vaccine, their body produces antibodies that pass through the placenta to the baby, providing passive immunity. This gives the baby early protection against RSV during the first few months of life, when they are most vulnerable.

Timing: The vaccine is given just before or during the RSV season, between weeks 32 and the end of 36 weeks of pregnancy (up until 36 weeks and 6 days). For the best protection, it's important to get the vaccine at least two weeks before birth so the antibodies have enough time to reach the baby.

Safety: ABRYSVO™ is an inactivated (non-live) vaccine that is safe for pregnant people and their developing babies. It is the only vaccine approved for use in pregnancy that has been intentionally tested in pregnant people during clinical trials. Other RSV vaccines are not approved for use in pregnancy.

Cost: The vaccine is not free (it costs about \$300) and can be purchased at select pharmacies.

Talk to your health care provider.

Talk to your health care provider to learn more about RSV prevention for your child, and to find out which option is best for you based on availability, eligibility, and other factors.

More information is available at:

- [BC Center for Disease Control - Respiratory Syncytial Virus](#)
- [BC Pharmacy Association - Respiratory Syncytial Virus \(RSV\) Vaccines in Pharmacies](#)
- [HealthLinkBC - Respiratory Syncytial Virus \(RSV\) Infection](#)

Reference: BC Pharmacy Association
www.bcpharmacy.ca/rsv-vaccines